Sign In
Last checked at 
31 Dec 2025 07:00
31 December 2025
Futura Medical plc
("Futura", "the Group" or the "Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, announces that for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 581,327,755 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 581,327,755 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Contacts:
Futura Medical plc
| Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
| investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com
|
Panmure Liberum Nominated Adviser and Broker | Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
| +44 (0)20 3100 2000
|
| ||
Turner Pope Investments (TPI) Ltd - Broker | Guy McDougall, Andrew Thacker | +44 (0) 20 3657 0050 |
| ||
Alma Strategic Communications | Rebecca Sanders-Hewett, Sam Modlin, Emma Thompson | +44 (0)20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.
WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.
Follow the stocks
